Related Experiment Video

Updated: Apr 29, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

12.5K

Clinical implications of BRAF mutation test in colorectal cancer

Ehsan Nazemalhosseini Mojarad1, Roya Kishani Farahani2, Mahdi Montazer Haghighi2

  • 1Gastroenterology and Liver Disease Research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Gastroenterology and Hepatology From Bed to Bench
|May 17, 2014
PubMed

Insights

BRAF mutations are increasingly recognized for their role in colorectal cancer (CRC) pathogenesis, prognosis, and predicting response to targeted therapies. Understanding BRAF alterations is crucial for personalized CRC treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) mutations are significant in colorectal cancer (CRC).
  • BRAF encodes a protein kinase in the RAS/RAF/MAPK pathway, influencing cell signaling and division.
  • BRAF mutations, similar to KRAS mutations, can lead to uncontrolled cellular proliferation.

Purpose of the Study:

  • To review the clinical significance of BRAF mutations in colorectal cancer.
  • To elucidate the impact of BRAF mutations on CRC pathogenesis, prognosis, and treatment response.
  • To highlight the utility of BRAF testing in differentiating sporadic CRC from Lynch syndrome.

Main Methods:

  • Literature review of studies on BRAF mutations in colorectal cancer.
  • Analysis of the role of BRAF in the RAS/RAF/MAPK signaling pathway.
  • Examination of BRAF mutation testing in clinical practice.

Main Results:

  • BRAF mutations influence CRC pathogenesis and prognosis.
  • BRAF testing aids in distinguishing sporadic CRC from Lynch syndrome.
  • BRAF status is important for predicting patient outcomes with targeted therapies.

Conclusions:

  • BRAF mutation testing is becoming standard in clinical laboratories for CRC management.
  • Understanding BRAF mutations is essential for personalized medicine in colorectal cancer.
  • BRAF alterations have implications for patient prognosis and therapeutic strategies.
Keywords:
BRAF mutationColorectal CancerPrognosis value

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81